- Home
- DHAI vs PMVP Comparison
DHAI vs PMVP Comparison
Compare DHAI & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- PMVP
- Stock Information
- Founded
- DHAI 2007
- PMVP 2013
- Country
- DHAI United States
- PMVP United States
- Employees
- DHAI N/A
- PMVP N/A
- Industry
- DHAI
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- DHAI
- PMVP Health Care
- Exchange
- DHAI NYSE
- PMVP Nasdaq
- Market Cap
- DHAI 10.5M
- PMVP 55.1M
- IPO Year
- DHAI N/A
- PMVP 2020
- Fundamental
- Price
- DHAI $0.22
- PMVP $1.09
- Analyst Decision
- DHAI
- PMVP Strong Buy
- Analyst Count
- DHAI 0
- PMVP 1
- Target Price
- DHAI N/A
- PMVP $5.00
- AVG Volume (30 Days)
- DHAI 2.1M
- PMVP 362.7K
- Earning Date
- DHAI 07-14-2025
- PMVP 08-07-2025
- Dividend Yield
- DHAI N/A
- PMVP N/A
- EPS Growth
- DHAI N/A
- PMVP N/A
- EPS
- DHAI N/A
- PMVP N/A
- Revenue
- DHAI $69,573,000.00
- PMVP N/A
- Revenue This Year
- DHAI N/A
- PMVP N/A
- Revenue Next Year
- DHAI N/A
- PMVP N/A
- P/E Ratio
- DHAI N/A
- PMVP N/A
- Revenue Growth
- DHAI 5.40
- PMVP N/A
- 52 Week Low
- DHAI $0.12
- PMVP $0.81
- 52 Week High
- DHAI $3.67
- PMVP $1.82
- Technical
- Relative Strength Index (RSI)
- DHAI 48.38
- PMVP 61.16
- Support Level
- DHAI $0.20
- PMVP $1.01
- Resistance Level
- DHAI $0.26
- PMVP $1.12
- Average True Range (ATR)
- DHAI 0.04
- PMVP 0.07
- MACD
- DHAI -0.00
- PMVP 0.01
- Stochastic Oscillator
- DHAI 23.33
- PMVP 64.00
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.